Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Johann S. De Bono" Clear advanced filters

  • Androgen receptor activation and signaling have a key role in the pathogenesis of castration-resistant prostate cancer. In this Review, Reid and colleagues assess the possible therapeutic strategy of inhibiting androgen biosynthesis by blocking the function of the enzyme CYP17.

    • Alison HM Reid
    • Gerhardt Attard
    • Johann S de Bono
    Reviews
    Nature Clinical Practice Urology
    Volume: 5, P: 610-620

  • There is an urgent need to accelerate the development of new molecularly targeted cancer therapeutics by improving early clinical anticancer drug evaluation. This article discusses current approaches and new strategies that should maximize benefit to patients and expedite the regulatory approval of new anticancer drugs.

    • Timothy A. Yap
    • Shahneen K. Sandhu
    • Johann S. de Bono
    Reviews
    Nature Reviews Cancer
    Volume: 10, P: 514-523

  • The progression of prostate cancer to castration-resistant prostate cancer (CRPC) poses considerable therapeutic challenges. Johann de Bono and colleagues review the identification of possible drug targets in CRPC, the evolving CRPC therapeutic landscape and what the future of the treatment of the disease may hold.

    • Timothy A. Yap
    • Alan D. Smith
    • Johann S. de Bono
    Reviews
    Nature Reviews Drug Discovery
    Volume: 15, P: 699-718

  • Iniparib showed promising results in randomized phase II trials in patients with triple-negative breast cancer; however, negative results from a phase III study in this disease setting, tempered enthusiasm for this agent. The authors of this Review scrutinize the development of iniparib from preclinical studies to registration trials, and identify and discuss the pitfalls in the development of anticancer drugs to prevent future late-stage trial failures.

    • Joaquin Mateo
    • Michael Ong
    • Johann S. de Bono
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 688-696